Geyer MC, et al. - In young people with cystic fibrosis (CF) and impaired glucose tolerance (IGT), researchers determined the acute effect of exenatide on postprandial glycaemia. In a double-blind randomized crossover trial, 6 participants with CF and IGT were studied on 2 days. Participants received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with 13C octanoate and pancreatic enzyme replacement after overnight fasting. After exenatide, gastric emptying was markedly slower, as assessed by time for 10% gastric emptying and peak ¹³CO₂ excretion. For the first time, investigators reported that exenatide in young people with CF and IGT corrects postprandial hyperglycaemia. In CF-related diabetes, glucagon-like peptide-1 (GLP-1) agonists are a candidate treatment.